Home LiteratureArticle Details
PMID: 27401919 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Mutation Drivers of Immunological Responses to Cancer.

Cancer immunology research ·Vol. 4 ·No. 9 ·2016-00-02 ·Pages 789-98

Porta-Pardo E, Godzik A

Abstract

In cancer immunology, somatic missense mutations have been mostly studied with regard to their role in the generation of neoantigens. However, growing evidence suggests that mutations in certain genes, such as CASP8 or TP53, influence the immune response against a tumor by other mechanisms. Identifying these genes and mechanisms is important because, just as the identification of cancer driver genes led to the development of personalized cancer therapies, a comprehensive catalog of such cancer immunity drivers will aid in the development of therapies aimed at restoring antitumor immunity. Here, we present an algorithm, domainXplorer, that can be used to identify potential cancer immunity drivers. To demonstrate its potential, we used it to analyze a dataset of 5,164 tumor samples from The Cancer Genome Atlas (TCGA) and to identify protein domains in which mutation status correlates with the presence of immune cells in cancer tissue (immune infiltrate). We identified 122 such protein regions, including several that belong to proteins with known roles in immune response, such as C2, CD163L1, or FCγR2A. In several cases, we show that mutations within the same protein can be associated with more or less immune cell infiltration, depending on the specific domain mutated. These results expand the catalog of potential cancer immunity drivers and highlight the importance of taking into account the structural context of somatic mutations when analyzing their potential association with immune phenotypes. Cancer Immunol Res; 4(9); 789-98. ©2016 AACR.

MeSH Terms
Antigens, Neoplasm/immunology Biomarkers Cadherins/chemistry,metabolism Complement System Proteins/chemistry,genetics,immunology Computational Biology/methods Gene Expression Profiling Humans Immunomodulation/genetics Models, Molecular Mutation Neoplasms/genetics,immunology,metabolism Phenotype Protein Binding Proteomics Structure-Activity Relationship beta Catenin/antagonists & inhibitors,chemistry,metabolism
Chemicals
Antigens, Neoplasm Biomarkers CTNNB1 protein, human Cadherins beta Catenin osteoblast cadherin Complement System Proteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Porta-Pardo Eduard
Program on Bioinformatics and Systems Biology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Godzik Adam
Program on Bioinformatics and Systems Biology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. adam@godziklab.org.
References (47)
47 references, click to expand
  1. The Pfam protein families database.
    Nucleic Acids Res. 2012 Jan;40(Database issue):D290-301 PMID: 22127870
  2. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  3. CellMix: a comprehensive toolbox for gene expression deconvolution.
    Bioinformatics. 2013 Sep 1;29(17):2211-2 PMID: 23825367
  4. Edgetic perturbation models of human inherited disorders.
    Mol Syst Biol. 2009;5:321 PMID: 19888216
  5. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway.
    Cell. 2009 Aug 7;138(3):576-91 PMID: 19631370
  6. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
    Nature. 2015 Jul 9;523(7559):231-5 PMID: 25970248
  7. Ensembl 2016.
    Nucleic Acids Res. 2016 Jan 4;44(D1):D710-6 PMID: 26687719
  8. Comprehensive assessment of cancer missense mutation clustering in protein structures.
    Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5486-95 PMID: 26392535
  9. Cancer and the complement cascade.
    Mol Cancer Res. 2010 Nov;8(11):1453-65 PMID: 20870736
  10. A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces.
    PLoS Comput Biol. 2015 Oct 20;11(10):e1004518 PMID: 26485003
  11. Inferring tumour purity and stromal and immune cell admixture from expression data.
    Nat Commun. 2013;4:2612 PMID: 24113773
  12. NetMHCpan, a method for MHC class I binding prediction beyond humans.
    Immunogenetics. 2009 Jan;61(1):1-13 PMID: 19002680
  13. Three-dimensional reconstruction of protein networks provides insight into human genetic disease.
    Nat Biotechnol. 2012 Jan 15;30(2):159-64 PMID: 22252508
  14. Plasminogen is a complement inhibitor.
    J Biol Chem. 2012 May 25;287(22):18831-42 PMID: 22451663
  15. TCPA: a resource for cancer functional proteomics data.
    Nat Methods. 2013 Nov;10(11):1046-7 PMID: 24037243
  16. dSysMap: exploring the edgetic role of disease mutations.
    Nat Methods. 2015 Mar;12(3):167-8 PMID: 25719824
  17. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.
    Nat Biotechnol. 2015 Nov;33(11):1152-8 PMID: 26372948
  18. Molecular and genetic properties of tumors associated with local immune cytolytic activity.
    Cell. 2015 Jan 15;160(1-2):48-61 PMID: 25594174
  19. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.
    J Exp Med. 2014 Oct 20;211(11):2231-48 PMID: 25245761
  20. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
    Blood. 2014 Jul 17;124(3):453-62 PMID: 24891321
  21. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells.
    Cancer Immunol Res. 2014 Mar;2(3):200-6 PMID: 24778316
  22. Innate immune recognition of cancer.
    Annu Rev Immunol. 2015;33:445-74 PMID: 25622193
  23. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser.
    Sci Rep. 2013 Oct 02;3:2652 PMID: 24084870
  24. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Sci Transl Med. 2013 Aug 28;5(200):200ra116 PMID: 23986400
  25. AIDA: ab initio domain assembly for automated multi-domain protein structure prediction and domain-domain interaction prediction.
    Bioinformatics. 2015 Jul 1;31(13):2098-105 PMID: 25701568
  26. Analysis of individual protein regions provides novel insights on cancer pharmacogenomics.
    PLoS Comput Biol. 2015 Jan 08;11(1):e1004024 PMID: 25568936
  27. e-Driver: a novel method to identify protein regions driving cancer.
    Bioinformatics. 2014 Nov 1;30(21):3109-14 PMID: 25064568
  28. The prognostic landscape of genes and infiltrating immune cells across human cancers.
    Nat Med. 2015 Aug;21(8):938-945 PMID: 26193342
  29. Modulation of the antitumor immune response by complement.
    Nat Immunol. 2008 Nov;9(11):1225-35 PMID: 18820683
  30. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.
    Cancer Immunol Res. 2015 Dec;3(12):1325-32 PMID: 26216416
  31. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
    Science. 2015 Oct 9;350(6257):207-211 PMID: 26359337
  32. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
    Immunity. 2013 Oct 17;39(4):782-95 PMID: 24138885
  33. Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs).
    Leukemia. 2014 Nov;28(11):2148-54 PMID: 24667943
  34. The role of complement in tumor growth.
    Adv Exp Med Biol. 2014;772:229-62 PMID: 24272362
  35. Getting personal with neoantigen-based therapeutic cancer vaccines.
    Cancer Immunol Res. 2013 Jul;1(1):11-5 PMID: 24777245
  36. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded.
    Bioinformatics. 2005 Aug 15;21(16):3435-8 PMID: 15955783
  37. The Cancer Genome Atlas Pan-Cancer analysis project.
    Nat Genet. 2013 Oct;45(10):1113-20 PMID: 24071849
  38. Neoantigens in cancer immunotherapy.
    Science. 2015 Apr 3;348(6230):69-74 PMID: 25838375
  39. HLA-binding properties of tumor neoepitopes in humans.
    Cancer Immunol Res. 2014 Jun;2(6):522-9 PMID: 24894089
  40. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.
    J Immunol. 2012 Sep 15;189(6):2985-94 PMID: 22914051
  41. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor.
    Bioinformatics. 2010 Aug 15;26(16):2069-70 PMID: 20562413
  42. Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions.
    Nucleic Acids Res. 2015 Jan;43(2):e10 PMID: 25392414
  43. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.
    J Immunol. 2012 Nov 1;189(9):4674-83 PMID: 23028051
  44. The STING pathway and regulation of innate immune signaling in response to DNA pathogens.
    Cell Mol Life Sci. 2011 Apr;68(7):1157-65 PMID: 21161320
  45. Robust enumeration of cell subsets from tissue expression profiles.
    Nat Methods. 2015 May;12(5):453-7 PMID: 25822800
  46. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Immunity. 2014 Nov 20;41(5):843-52 PMID: 25517616
  47. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex.
    Nature. 2015 Jul 30;523(7562):621-5 PMID: 26123024
Article Info
Journal
Cancer immunology research
Abbr.
Cancer Immunol Res
ISSN
2326-6074
Published
2016-00-02
Epub
2016-00-11
Pages
789-98
Language
English
Region
United States
NLM ID
101614637
PMCID
PMC5886853
Subset
IM
Grants
NIGMS NIH HHS · P01 GM063208 · United States
NCI NIH HHS · P30 CA030199 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com